🇺🇸 FDA
Patent

US 10221455

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

granted A61KA61K2039/6031A61K2039/6056

Quick answer

US patent 10221455 (Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy) held by BIOVERATIV THERAPEUTICS INC. expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2039/6031, A61K2039/6056, A61K38/21, A61K38/37